汇宇制药-W
(688553)
| 流通市值：54.65亿 | | | 总市值：67.41亿 |
| 流通股本：5.07亿 | | | 总股本：6.26亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 551,856,179.99 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 |
| 营业收入 | 551,856,179.99 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 |
| 二、营业总成本 | 471,782,101.01 | 241,878,348.21 | 923,789,392.55 | 685,551,126.24 |
| 营业成本 | 128,335,558.8 | 56,059,983.61 | 203,595,463.36 | 144,711,526.21 |
| 税金及附加 | 5,325,900.78 | 1,905,170.82 | 9,970,620.9 | 5,643,926.25 |
| 销售费用 | 168,900,303.58 | 86,603,675.57 | 359,230,759.2 | 272,034,014.01 |
| 管理费用 | 49,175,248.68 | 27,757,911.11 | 97,058,090.21 | 64,089,471.19 |
| 研发费用 | 146,610,715.53 | 66,821,499.28 | 302,705,012.35 | 231,620,158.48 |
| 财务费用 | -26,565,626.36 | 2,730,107.82 | -48,770,553.47 | -32,547,969.9 |
| 其中:利息费用 | 6,169,136.04 | 3,346,891.97 | 9,781,566.85 | 6,675,992.28 |
| 其中:利息收入 | 53,979,003.66 | 12,924,454.53 | 53,050,928.95 | 28,997,397.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -30,419,505.37 | -27,686,556.96 | -167,003,663.92 | -160,998,824.61 |
| 加:投资收益 | -7,375,370.35 | 7,584,604 | 477,465.87 | 3,332,115.82 |
| 资产处置收益 | - | - | 1,887.15 | 1,887.15 |
| 资产减值损失(新) | -4,293,268.24 | -1,966,016.88 | -5,406,404.61 | -1,467,728.97 |
| 信用减值损失(新) | -3,063,987.72 | 928,124.51 | -2,573,927.9 | -1,416,397.06 |
| 其他收益 | 13,100,119.72 | 9,802,246.24 | 33,924,260.17 | 27,040,728.9 |
| 四、营业利润 | 48,022,067.02 | 15,990,634.05 | -66,224,823.77 | -77,308,939.17 |
| 加:营业外收入 | 1,900,104.35 | 1,122,357.74 | 2,897,450.29 | 1,827,481.94 |
| 减:营业外支出 | 599,720.12 | 603,475.34 | 985,463.93 | 803,052.14 |
| 五、利润总额 | 49,322,451.25 | 16,509,516.45 | -64,312,837.41 | -76,284,509.37 |
| 减:所得税费用 | -7,741,453.58 | -5,210,470.69 | -33,765,083.27 | -21,214,658.68 |
| 六、净利润 | 57,063,904.83 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 57,063,904.83 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 57,648,572.7 | 21,869,139.53 | -24,961,496.76 | -50,804,666 |
| 少数股东损益 | -584,667.87 | -149,152.39 | -5,586,257.38 | -4,265,184.69 |
| 扣除非经常损益后的净利润 | 78,098,776.86 | 30,868,465.47 | 85,090,444.94 | 79,560,578.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.05 | -0.06 | -0.12 |
| (二)稀释每股收益 | 0.09 | 0.05 | -0.06 | -0.12 |
| 八、其他综合收益 | -1,508,628.45 | 622,982.18 | -1,957,391.72 | -2,111,898.33 |
| 归属于母公司股东的其他综合收益 | -1,508,628.45 | 622,982.18 | -1,957,391.72 | -2,111,898.33 |
| 九、综合收益总额 | 55,555,276.38 | 22,342,969.32 | -32,505,145.86 | -57,181,749.02 |
| 归属于母公司股东的综合收益总额 | 56,139,944.25 | 22,492,121.71 | -26,918,888.48 | -52,916,564.33 |
| 归属于少数股东的综合收益总额 | -584,667.87 | -149,152.39 | -5,586,257.38 | -4,265,184.69 |
| 公告日期 | 2026-08-22 | 2026-04-25 | 2026-04-25 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |